Results 131 to 140 of about 38,272 (314)

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source

Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol. [PDF]

, 2017
INTRODUCTION: Sodium glucose cotransporter 2 (SGLT2) inhibitors are effective blood-glucose-lowering medications with beneficial effects on body weight in patients with type 2 diabetes mellitus (T2DM).
Boyland, EJ, Cuthbertson, DJ, Halford, JCG, Harrold, JA, Kemp, GJ, Rajeev, SP, Roberts, C, Sprung, VS, Stancak, A, Wilding, JPH   +9 more
core   +2 more sources

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study [PDF]

, 2018
Serge Jabbour, Juan P. Frías, Cristian Guja, Elise Hardy, Azazuddin Ahmed, Peter Öhman   +5 more
openalex   +1 more source

Benefit/risk profile of dapagliflozin 5 mg in the DEPICT ‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m ² [PDF]

, 2020
Chantal Mathieu, Paresh Dandona, Andreas L. Birkenfeld, Troels Krarup Hansen, Nayyar Iqbal, John Xu, Enrico Repetto, Markus F. Scheerer, Fredrik Thorén, Moshe Phillip   +9 more
openalex   +1 more source

Effect of Multiple Doses of Sparsentan on the Single‐Dose Pharmacokinetics of Dapagliflozin: An Open‐Label Drug–Drug Interaction Study in Healthy Adults [PDF]

, 2023
Shang‐Chiung Chen, Danlin Cai, Claire Winnett, Mai Thanh Thi Nguyen, Neeraj Verma, Kai Liu, Priscila Preciado   +6 more
openalex   +1 more source

A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin

Diabetes, obesity and metabolism
To investigate the efficacy and safety of pioglitazone compared to placebo when added to metformin plus dapagliflozin, a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, for patients with type 2 diabetes mellitus (T2DM).
Soo Lim, Seung-Hwan Lee, Kyung-Wan Min, C. B. Lee, Sang Yong Kim, Hye Jin Yoo, N. Kim, Jae Hyeon Kim, Seungjoon Oh, Jong Chul Won, H. Kwon, Mi Kyung Kim, J. H. Park, In-Kyung Jeong, Sungrae Kim   +14 more
semanticscholar   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial [PDF]

, 2018
Aims/hypothesis: In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 ...
Fitchett, David, George, Jyothis T., Hantel, Stefan, Sattar, Naveed, Zinman, Bernard   +4 more
core   +1 more source

Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial

Clinical Kidney Journal
Background The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial enrolled patients with estimated glomerular filtration rate 25–75 mL/min/1.73 m2 and urine albumin-to-creatinine ratio >200 mg/g.
Phil McEwan, Jason A. Davis, Peter D. Gabb, David C. Wheeler, P. Rossing, Glenn M. Chertow, Ricardo Correa-Rotter, Kouichi Tamura, Salvatore Barone, Juan José Garcia Sanchez   +9 more
semanticscholar   +1 more source

Response to the Nephrological perspectives on the underutilization of SGLT2i in heart failure and chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 1492-1493, April 2025.
Umut Kocabas
wiley   +1 more source